Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel liposome (Puripharm)
- Development stage
- Preclinical
- Lead developer
- SPARC
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
PR-1 is a liposomal nanoparticle formulation of the cytotoxic agent docetaxel, developed by Puripharm. Docetaxel is a taxane that promotes the assembly of tubulin into stable microtubules and inhibits their disassembly, which leads to a marked decrease in free tubulin. This stabilization interferes with the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions, ultimately inducing cell cycle arrest and apoptosis. The liposomal formulation is intended to enhance the therapeutic index of docetaxel by improving its solubility, prolonging circulation time, and increasing tumor-specific delivery via the enhanced permeability and retention (EPR) effect, while potentially mitigating side effects associated with traditional surfactants like polysorbate 80.
- Other names
- 注射用多西他赛脂质体Liposomal DocetaxelPR-1PR1PR 1
02
Targets
BCL-2 (BCL-2 family)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on docetaxel liposome (Puripharm).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel liposome (Puripharm).